[1]Young RM, Jamshidi A,Davis G,et al. Current trends in the surgical management and treatment of adult glioblastoma[J]. Ann Transl Med, 2015, 3(9): 121.
[2]Lorimer CF, Hanna C, Saran F, et al. Challenges to treating older glioblastoma patients: the influence of clinical and tumour characteristics on survival outcomes [J]. Clin Oncol (R Coll Radiol), 2017,29(11): 739-747.
[3]Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas [J]. Acta Neuropathol, 2010, 120(6): 707-718.
[4]Nobusawa S, Watanabe T, Kleihues P, et al. DH1 mutations as molecular signature and predictive factor of secondary glioblastomas[J]. Clin Cancer Res, 2009, 15(19): 6002-6007.
[5]Love MI, Huber W, Anders S. Anders. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2[J]. Genome Biol, 2014, 15(12): 550.
[6]Filimon A, Zurac SA, Milac AL, et al. Value of dopachrome tautomerase detection in the assessment of melanocytic tumors[J]. Melanoma Res, 2014, 24(3): 219-236.
[7]Wang K, Chen D, Qian Z, et al. Hedgehog/Gli1 signaling pathway regulates MGMT expression and chemoresistance to temozolomide in human glioblastoma[J]. Cancer Cell Int, 2017,17(117):1-12.
[8]Tong Y, Xu Y, Scearce-Levie K, et al. COL25A1 triggers and promotes Alzheimer’s disease-like pathology in vivo[J]. Neurogenetics, 2010, 11(1): 41-52.
[9]Zheng H, Ying H, Yan H, et al. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation[J]. Nature, 2008, 455(7216): 1129-1133.
[10]Han B, Cai J, Gao W, et al. Loss of ATRX suppresses ATM dependent DNA damage repair by modulating H3K9me3 to enhance temozolomide sensitivity in glioma[J]. Cancer Lett, 2018, 419: 280-290.
[11]Russo A, O’Bryan JP. Intersectin 1 is required for neuroblastoma tumorigenesis[J]. Oncogene, 2012, 31(46): 4828-4834.
|